Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

OSR Holdings (NASDAQ: OSRH) said Vaximm, its Swiss subsidiary, received a binding term sheet from BCM Europe for a proposed global exclusive license of VXM01.

Rhea-AI Summary

OSR Holdings (NASDAQ: OSRH) said Vaximm, its Swiss subsidiary, received a binding term sheet from BCM Europe for a proposed global exclusive license of VXM01. Key financial terms include a $30 million upfront payment (50% cash, 50% digital assets) and up to $815 million in aggregate milestone payments weighted toward clinical and development achievements. The Fund proposed as licensee would pass through future sublicense royalties to Vaximm subject to reconciliation. Vaximm's board will seek an independent fairness opinion and targets a definitive agreement by end of May 2026, subject to customary conditions and approvals.

Positive

• Upfront consideration of $30M
• Potential $815M in aggregate milestone payments
• Proposal grants global exclusive development and commercialization rights
• Board engagement of independent fairness opinion

Negative

• 50% of upfront payable in digital assets, increasing payment risk
• Definitive agreement not executed; subject to board review and approvals
• Milestones weighted to clinical success, tying value to trial outcomes
• Target closing by May 2026 remains conditional and uncertain

Argus Jan 12 session

+8.26% close to close Open Argus

Details

News Market Reaction – OSRH

On Jan 12, the day this news came out, OSRH closed 8.26% above the previous close.

Data tracked by StockTitan Argus for the Jan 12 session.

Key Figures

Upfront payment: $30 million Milestone potential: $815 million Cash component: 50% of upfront +2 more

Upfront payment

$30 million

Binding term sheet upfront for VXM01 license

Milestone potential

$815 million

Aggregate clinical and development milestone payments under proposed license

Cash component

50% of upfront

Portion of $30 million upfront payable in cash

Digital asset component

50% of upfront

Portion of $30 million upfront payable in digital assets

Target execution date

End of May 2026

Best-efforts target to sign definitive global exclusive license

Historical Context

5 past events · Latest: Nov 14

5 events

1. Nov 14

   Management change

   24h Move

   -8.8%

   Appointed Vaximm co-founder as CEO to lead immuno-oncology expansion.

2. Nov 21

   Licensing term sheet

   24h Move

   +23.4%

   Non-binding VXM01 global license term sheet with $20M upfront and milestones.

3. Dec 01

   Investor conference

   24h Move

   -4.3%

   Announcement of Emerging Growth Conference corporate overview presentation.

4. Dec 02

   Term sheet update

   24h Move

   -1.6%

   Shortened VXM01 term sheet exclusivity to three months with unchanged terms.

5. Dec 19

   M&A approval

   24h Move

   +13.7%

   Woori IO shareholders approved share exchange to become OSR subsidiary.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

binding term sheet, global exclusive licensing transaction, investment vehicle, digital assets, +4 more

8 terms

binding term sheet financial

"Vaximm AG, has received a binding term sheet from BCM Europe AG"

A binding term sheet is a short, signed document that sets out the main deal points—price, ownership, key rights and responsibilities—and includes specific promises that are legally enforceable. Think of it as a shopping list with certain items you and the seller have already agreed must happen, not just a wish list. Investors watch for binding term sheets because they signal real commitment, change the odds of a deal closing, and create legal obligations that can affect valuation, financing and risk.

global exclusive licensing transaction financial

"interest in entering a global exclusive licensing transaction for VXM01"

A global exclusive licensing transaction is a deal where the owner of a product, technology, or drug grants one other company the sole right to develop, make, sell, or distribute it worldwide. For investors it matters because such a deal can create predictable revenue streams (upfront payments, milestone payments, royalties) for the owner while shifting commercialization costs and risks to the licensee, which can materially change expected future cash flows and company value—think of it as selling the worldwide franchise rights to a single partner.

investment vehicle financial

"intends to establish and manage a dedicated investment vehicle, anchored by a"

An investment vehicle is any product or arrangement used to hold, grow, or manage money—such as stocks, bonds, mutual funds, exchange-traded funds, real estate trusts, or savings accounts. Think of it as a container or tool in a toolbox that shapes risk, return, and how easily you can buy or sell an asset. For investors it matters because the choice of vehicle affects potential gains, losses, fees, taxes, and how quickly you can access your cash.

digital assets financial

"an upfront payment of $30 million, structured as 50% cash and 50% digital assets"

Digital assets are electronic files or representations of value stored electronically, such as cryptocurrencies, digital tokens, or digital art. They matter to investors because they can be bought, sold, and used for transactions much like physical assets, but exist entirely in digital form, offering new opportunities for investment and financial innovation.

View in glossary

fairness opinion financial

"engage an independent third-party valuation firm ... to provide a fairness opinion"

A fairness opinion is a professional assessment that evaluates whether the terms of a financial deal, such as a merger or acquisition, are fair from a financial point of view. It helps investors and stakeholders understand if the deal is reasonable and balanced, much like an independent expert giving an unbiased judgment on whether a price or agreement is fair. This assurance can increase confidence that the transaction is fair for all parties involved.

immunotherapy medical

"VXM01, Vaximm's lead immunotherapy candidate"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

royalty revenues financial

"the Fund would pass through royalty revenues received from a future sublicensee"

Payments a company receives when others use its intellectual property, brand, natural resources or copyrighted work—similar to collecting rent when someone uses your property. Royalty revenues matter to investors because they are often steady, recurring cash flows that can boost valuation and reduce reliance on direct sales; their size and predictability affect profitability, growth prospects and the risk profile of an investment.

sublicensee regulatory

"royalty revenues received from a future sublicensee or commercial partner"

A sublicensee is a third party that a licensee authorizes to use or sell intellectual property, technology, products, or rights that the licensee originally obtained from the owner. Think of it like a tenant subletting an apartment: the sublicensee gets many of the same practical rights but typically through the middleman rather than directly from the owner, which matters to investors because sublicensing can expand revenue, spread risk, dilute control, and affect royalty flows and legal exposure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BELLVUE, Wash., Jan. 12, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG confirming BCM Europe's interest in entering a global exclusive licensing transaction for VXM01, Vaximm's lead immunotherapy candidate.

Under the terms of the binding term sheet, BCM Europe intends to establish and manage a dedicated investment vehicle, anchored by a strategic investor, tentatively named BCM Decentralized Science Investors I, LP (the "Fund"), which would act as the Licensee under the contemplated definitive license agreement. The proposed transaction structure includes:

• the grant of global exclusive rights to develop and commercialize VXM01 to the Fund;
• an upfront payment of $30 million, an increase from the previously discussed non-binding proposal, structured as 50% cash and 50% digital assets;
• aggregate milestone payments of up to $815 million, with the milestone structure weighted primarily toward clinical and development achievements, rather than operational milestones; and
• a royalty pass-through structure, pursuant to which the Fund would pass through royalty revenues received from a future sublicensee or commercial partner (the "Ultimate Licensee") to Vaximm, subject to a reconciliation mechanism reflecting the difference, if any, between milestone payments received from the Ultimate Licensee and the aggregate milestone payments paid by the Fund to Vaximm.

Vaximm's Board of Directors will conduct a comprehensive review of the binding term sheet and has determined to engage an independent third-party valuation firm with recognized expertise in life-science and biotechnology licensing transactions to provide a fairness opinion. The fairness opinion will evaluate whether the proposed transaction is fair and reasonable to Vaximm and OSR Holdings' shareholders from a financial point of view, based on the fair market value of VXM01.

"VXM01 has demonstrated encouraging clinical and safety data across multiple indications. The receipt of this binding term sheet reflects the growing recognition of VXM01's potential value as a differentiated immunotherapy asset and underscores BCM Europe's genuine intent and capability to close the deal," said Andreas Niethammer, CEO of Vaximm AG. "If completed, this proposed licensing framework would provide a strong foundation to advance VXM01 into later-stage development while preserving long-term upside for Vaximm."

The parties currently target, on a best-efforts basis, to negotiate and execute a definitive global exclusive license agreement by the end of May 2026, subject to customary conditions, including the completion of Vaximm's board review, receipt of an independent third-party fairness opinion, final documentation, and required approvals.

"This binding term sheet represents a meaningful progression from earlier discussions and reflects third-party confidence in the value of VXM01," said Tim Smith, Head of Investor Relations at OSR Holdings. "While we remain mindful that a definitive agreement has not yet been executed, we believe the proposed structure, together with an independent valuation review, demonstrates a disciplined approach to unlocking long-term value for OSR Holdings' shareholders."

About OSR Holdings, Inc.

OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in healthcare and wellness. Through its subsidiaries, OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve global health outcomes. Learn more at www.OSR-Holdings.com.

About Vaximm AG

Vaximm AG is a privately held Swiss-German biotechnology company and a wholly owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary orally administered T-cell vaccination platform harnesses live, attenuated bacterial vectors to deliver tumor-associated antigens, inducing robust cellular immune responses. Lead candidate VXM01, targeting VEGFR-2, has demonstrated clinical activity and safety in multiple cancer indications.

About BCM Europe AG

BCM Europe AG is a Switzerland-based life sciences investment entity and the largest shareholder of OSR Holdings.

Forward-Looking Statements

This press release contains forward-looking statements regarding the potential licensing agreement between Vaximm AG and BCM Europe AG, the development and commercialization of VXM01, and the expected benefits of the collaboration. Actual results may differ materially due to risks and uncertainties, including the possibility that a definitive agreement may not be reached or anticipated milestones may not be achieved. OSR Holdings, Vaximm, and BCM Europe AG do not assume any obligation to update these statements except as required by law.

Media & Investor Contact

OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vaximm-an-osr-company-receives-binding-term-sheet-from-bcm-europe-for-global-exclusive-license-of-vxm01-with-30m-upfront-and-up-to-815m-in-milestones-302658498.html

SOURCE OSR Holdings

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the headline financial terms of the OSRH VXM01 term sheet?

The term sheet outlines a $30M upfront payment and up to $815M in milestone payments.

How will OSR Holdings receive the $30M upfront for VXM01 (OSRH)?

The $30M is structured as 50% cash and 50% digital assets under the term sheet.

What is the proposed timeline for OSR Holdings to finalize the VXM01 license?

The parties target negotiation and execution of a definitive agreement by end of May 2026, subject to conditions.

What approvals does OSR Holdings need before the VXM01 license becomes binding?

Required steps include Vaximm board review, an independent fairness opinion, final documentation, and customary approvals.

How are future royalties handled under the proposed OSRH VXM01 deal?

The Fund would pass through royalties received from an ultimate sublicensee to Vaximm, subject to a reconciliation mechanism.

Does the term sheet guarantee full payment to OSR Holdings for VXM01?

No; the upfront is committed under the term sheet but the milestone payments and final deal depend on future conditions and approvals.